title: Breast cancer: updated guideline recommendations for HER2 testing.
abstract: The recently updated HER2 testing guidelines by ASCO and the College of American Pathologists (CAP) are a significant step towards personalized medicine. It is excellent news that such great effort has been put into standardizing biomarker assessment. Undoubtedly, these recommendations will improve the analytical validity of HER2 testing, its clinical utility and the communication among health-care providers.
authors: Division of Oncology, School of Medicine, University of Nottingham, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK.
authors: Emad A
authors: EA
authors: Rakha
authors: Division of Oncology, School of Medicine, University of Nottingham, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK.
authors: Ian O
authors: IO
authors: Ellis
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D005260:Female; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D017410:Practice Guidelines as Topic; D057285:Precision Medicine / Q000379:methods*; D011237:Predictive Value of Tests; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000302:isolation & purification*; D016387:Women's Health
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human